Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS/Sanofi-Aventis To Study Plavix Efficacy Concerns

This article was originally published in The Pink Sheet Daily

Executive Summary

Genetics and concomitant PPI use are possible reasons for the anti-platelet drug’s reduced effectiveness in some patients, according to an FDA “Early Communication.”

You may also be interested in...



Takeda's Kapidex: Can A Study On Plavix Shake Up The PPI Market?

Takeda could position Kapidex as the proton pump inhibitor of choice if a new clinical trial confirms its interaction profile is more agreeable than other PPI products

Takeda's Kapidex: Can A Study On Plavix Shake Up The PPI Market?

Study of how several PPIs might affect the pharmacokinetics and pharmacodynamics of Plavix could impact formulary placement.

Takeda's Kapidex: Can A Study On Plavix Shake Up The PPI Market?

Study of how several PPIs might affect the pharmacokinetics and pharmacodynamics of Plavix could impact formulary placement.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel